ITPP Powder

Unit Size

Want a discount? Become a member!


Myo-Inositol Trispyrophosphate (ITPP) is a relatively new compound that improves the ability of haemoglobin in red blood cells to release oxygen into tissues. It has the chemical formula C6H15O15P3 and the molecular weight 420.096 g/mol.

ITPP Benefits and Uses

Myo-Inositol Trispyrophosphate (ITPP) is a recently discovered compound based on Myo-Inositol with significance in its ability to alter the oxygen-disassociation curve for haemoglobin in red blood cells. ITPP is of great interest to medical researchers studying the pathology of diseases related to hypoxia (low oxygen levels).

In animal trials, an acute and sustained impact on the oxygen binding affinity of hemoglobin was observed for 48 hours after a single administration of ITPP, and effects could still be seen in blood serum samples up to 12 days later! Anecdotally, many ITPP users have noted improved energy levels, an increase in exercise capacity, and a decrease in fatigue for up to a week following a single serving.

Research interest in ITPP is growing due to its energy-enhancing properties.

  • Myo-Inositol Trispyrophosphate (ITPP) is known by a number of alternative names including:
  • Inositol Tripyrophosphate
  • Inositol 1,4,5-trisphosphate
  • Myo Inositol Trispyrophosphate
  • Sometimes confused for: Inositol Triphosphate (IT3)
  • [(1R,2S,3R,4R,5S,6R)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate
  • IP3

Scientific Consensus

This is a relatively new product and there is very limited research on its effects and benefits in humans. Further research is necessary to fully understand the significance of its effects and adverse effects. Use with caution.

DO NOT EXCEED THE RECOMMENDED SERVING SIZE. Use with caution. Do not use if pregnant or breastfeeding.

PLEASE NOTE: ITPP is currently on the World Anti-Doping Agency list, and may NOT be used by professional athletes.

Read More
The statements on this page have not been evaluated by the FDA. The products on this page are not intended to diagnose, treat, cure, or prevent any disease.
November 24, 2019
ITPP Powder

Great for energy, endurance and performance. Makes me feel young. Great product.

Serving size is 1000 mg. As a dietary supplement, take 1-2 servings up to 2 times per day. Please start with the lowest suggested single serving quantity to assess response.

Supplement Facts

Serving size: 1000mg
Servings per container:
Amount per serving: % DV

Myo-Inositol Trispyrophosphate

1000 mg
LiftMode offers a variety of unit sizes of HPLC-tested ITPP Powder, including a a 1g unit, a 2g unit, a 5g unit and a 10g unit. Our ITPP Powder is of the highest quality.
Store securely in a dry cool location away from direct sunlight. Keep out of reach of children and pets. Do not take this or any other supplement, and instead consult doctor about use, if you are under the age of 18, pregnant or breastfeeding, taking prescription or OTC / nonprescription drugs, or if you have any known or suspected medical conditions. Do not use if product safety seal was damaged or missing upon receipt.
Read More
Free from additives and fillers
Gluten Free
HPLC Lab tested
Money back guarantee
Science backed

Scientifically Tailored Ingredients

ITPP (Myo-inositol Trispyrophosphate) is an inositol phosphate and allosteric effector of hemoglobin that helps regulate the uptake and release of oxygen in red blood cells.

This enrichment in oxygen delivery has been found to have physical performance-enhancing properties and to help ease stress caused by low oxygen levels.

– Increases Oxygen Saturation in Tissues
– Low Level of Research
– Improves Energy Levels

Duarte , C. D., Greferath , R., Nicolau , C., & Lehn, J.-M. (2010). Myo-inositol Trispyrophosphate: A Novel Allosteric Effector of Hemoglobin with High Permeation Selectivity across the Red Blood Cell Plasma Membrane. ChemBioChem, 11(18), 2543–2548. doi:10.1002/cbic.201000499.

Lam, G., Zhao, S., Sandhu, J., Yi, R., Loganathan, D., & Morrissey, B. (2013). Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP. Drug Testing and Analysis, 6(3), 268–276. doi:10.1002/dta.147.

Görgens, C., Guddat, S., Schänzer, W., & Thevis, M. (2014). Screening and confirmation of myo-inositol trispyrophosphate (ITPP) in human urine by hydrophilic interaction liquid chromatography high resolution / high accuracy mass spectrometry for doping control purposes. Drug Testing and Analysis, 6(11-12), 1102–1107. doi:10.1002/dta.1700.

Raykov, Z., Grekova, S. P., Bour, G., Lehn, J. M., Giese, N. A., Nicolau, C., & Aprahamian, M. (2013). Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. International Journal of Cancer, 134(11), 2572–2582. doi:10.1002/ijc.28598.

Kieda, C., Greferath, R., Crola Da Silva, C., Fylaktakidou, K. C., Lehn, J.-M., & Nicolau, C. (2006). Suppression of hypoxia-induced HIF-1 and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proceedings of the National Academy of Sciences, 103(42), 15576–15581. doi:10.1073/pnas.0607109103